|Bid||0.00 x 1200|
|Ask||0.00 x 800|
|Day's Range||17.81 - 18.74|
|52 Week Range||7.45 - 30.10|
|Beta (5Y Monthly)||1.88|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 02, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||39.40|
Subscribe to Yahoo Finance Plus to view Fair Value for PTGX
The ICONIC program now includes four Phase 3 studies evaluating JNJ-2113; Co-primary endpoints for all four studies are PASI-90 and/or IGA 0 or 1Protagonist eligible to receive $115 million milestone upon achieving the co-primary endpoints in any ...
NEWARK, CA / ACCESSWIRE / November 16, 2023 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on November 15, 2023, it issued inducement awards to two recently hired employees in accordance with the terms of their employment offer ...
Maybe you could find out which stocks a well-known company that has been successful for a long time really likes -- a company such as Johnson & Johnson (NYSE: JNJ). Here are the three stocks that J&J is betting the most on. As of Sept. 30, 2023, Johnson & Johnson's biggest investment was in Legend Biotech (NASDAQ: LEGN).